logo
#

Latest news with #MazenBachir

Abu Dhabi, Abbott Partner to Boost Local Pharma Sector
Abu Dhabi, Abbott Partner to Boost Local Pharma Sector

TECHx

time21-06-2025

  • Health
  • TECHx

Abu Dhabi, Abbott Partner to Boost Local Pharma Sector

Home » Smart Sectors » Healthcare » Abu Dhabi, Abbott Partner to Boost Local Pharma Sector The Department of Health, Abu Dhabi (DoH), the healthcare sector regulator in Abu Dhabi, announced a strategic partnership with global healthcare leader Abbott. The agreement was signed during the BIO International Convention held in Boston, USA. The partnership aims to localise pharmaceutical manufacturing in Abu Dhabi. It also focuses on advancing digital health solutions across the emirate. Officials revealed that the collaboration builds on Abu Dhabi's advanced life sciences infrastructure. This move supports the emirate's goal to reduce dependency on imports and strengthen supply chain resilience. It further reflects Abu Dhabi's commitment to fostering a self-sufficient and sustainable healthcare ecosystem. Dr. Noura Al Ghaithi, Undersecretary of DoH, stated that the partnership follows the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi. She added that the emirate is equipped with an integrated infrastructure to support local manufacturing and R&D. She said the agreement would position Abu Dhabi as a regional healthcare hub and leader in life sciences. According to her, aligning DoH's strategic vision with Abbott's global expertise will accelerate the delivery of innovative healthcare products and solutions. The collaboration is built around four key pillars: Localising Abbott's pharmaceutical portfolio and developing biosimilars. Advancing digital transformation through electronic patient information leaflets. Launching education programs to strengthen the healthcare workforce. Supporting regulatory alignment and joint R&D initiatives. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, reported that this partnership will enhance healthcare resilience and innovation in Abu Dhabi. He highlighted Abbott's ongoing commitment to the UAE's healthcare system. He noted that the partnership will also include digitising life sciences product information and launching training initiatives to build local capabilities. In addition, both parties will explore opportunities for joint research and development. DoH also reported that a high-level delegation has embarked on a strategic mission to the United States from 15 to 21 June 2025. The delegation will conduct over 20 meetings with public and private sector leaders. These meetings aim to promote knowledge exchange, attract investments, and sign new agreements that accelerate advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes: Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, and PureHealth. Etihad Cargo, New York University Abu Dhabi, Khalifa University, startAD, and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). This announcement highlights Abu Dhabi's global ambitions in life sciences and healthcare innovation.

The Department of Health – Abu Dhabi and Abbott Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi - Middle East Business News and Information
The Department of Health – Abu Dhabi and Abbott Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi - Middle East Business News and Information

Mid East Info

time21-06-2025

  • Health
  • Mid East Info

The Department of Health – Abu Dhabi and Abbott Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi - Middle East Business News and Information

During BIO International Convention in Boston USA, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership to localise manufacturing of pharmaceuticals in Abu Dhabi and advance digital health solutions. Leveraging Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare ecosystem. H.E. Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said: 'Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences. By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community.' The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development initiative. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant said: 'Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi. Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE.' Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 to 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions.

DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi
DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi

Al Etihad

time20-06-2025

  • Health
  • Al Etihad

DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi

20 June 2025 22:37 BOSTON (WAM) Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership during the BIO International Convention in Boston agreement aims to localise the manufacturing of pharmaceuticals in Abu Dhabi and advance digital health Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said, 'Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences." She added, "By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community.'The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development his part, Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, said, 'Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi." Bachir added, "Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE.'Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 - 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the US, aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI).

PHRMAG appoints new Executive Committee for 2025–2027
PHRMAG appoints new Executive Committee for 2025–2027

Zawya

time11-02-2025

  • Business
  • Zawya

PHRMAG appoints new Executive Committee for 2025–2027

Dubai, United Arab Emirates: The Pharmaceutical Research and Manufacturers Association Gulf (PHRMAG) is pleased to announce the appointment of its new Executive Committee (EC) for the term 2025–2027. This diverse and accomplished group of industry leaders is dedicated to fostering innovation, collaboration, and sustainable access to life-saving medicines across the Gulf region. Founded in 2005, PHRMAG represents 29 leading global biopharmaceutical research companies in the region. Dedicated to advancing innovation and patient care, the association collaborates with health authorities and healthcare systems to enhance access to treatments while ensuring transparency and ethical conduct through its globally aligned Code of Ethics. The newly appointed EC includes Sameh Elfangary, as Chairman and Cluster President at AstraZeneca GCC & Pakistan; Ashraf Mallak, Vice Chairman and Managing Director GCC at MSD; Ahmed Abu El Fadl, EC Member and General Manager Gulf at Merck Serono; Diederik Kok, EC Member and Head of GCC at Biogen; Elhussein Abdellatif, EC Member and General Manager Gulf Levant at AbbVie Biopharmaceuticals GmbH; Mazen Bachir, the former Chairman and now serving as EC Member and Regional Director Gulf, Levant & Emerging Markets at Abbott; and Pedro Matos Rosa, EC Member and General Manager at Johnson & Johnson Innovative Medicines Gulf. Sameh Elfangary, the newly appointed Chairman, said "I am both honored and humbled to lead PHRMAG's Executive Committee for the 2025–2027 term. On behalf of the member companies, I would like to extend our gratitude to the former Chairman, Mazen Bachir and the outgoing EC for their invaluable leadership contributions over the last couple of years, which further builds on the solid 20-year foundation of PHRMAG. The healthcare ecosystem in our region is undergoing fast-paced transformation, bringing novel mix of opportunities and challenges. As we move forward, together we will collaborate to shape an even more thriving future, and we will remain dedicated to the PHRMAG's mission of fostering innovation, sustaining an equitable patient access to life-changing care, while we continue championing transparency and integrity.' Key achievements of PHRMAG's 2023–2025 term and Executive Committee include strengthening industry collaboration with key stakeholders such as the Emirates Drug Establishment (EDE) and the Department of Health Abu Dhabi to advance sustainable healthcare initiatives. The outgoing committee successfully engaged in pivotal events like Abu Dhabi Global Healthcare Week and the BIO International Convention, reinforcing the Gulf region's position as a leader in pharmaceutical innovation. PHRMAG's Working Groups also made significant contributions during this term, driving impactful initiatives across various areas. The Ethics & Compliance Working Group continued to champion ethical practices, fostering trust and transparency throughout the industry. The IP Policy Working Group made considerable strides in emphasizing on intellectual property frameworks and facilitating dialogue on regulatory policies to enable access to innovative treatments. Notably, in 2024, one of PHRMAG's collaborations included partnering with the U.S. Chamber of Commerce and the GCC Patent Office to host a pivotal roundtable on the state of intellectual property in the GCC, highlighting the critical role of robust IP protections in shaping the region's patent ecosystem. PHRMAG extends its gratitude to the outgoing committee for their tireless efforts and dedication to advancing healthcare in the Gulf. Their leadership has significantly impacted the pharmaceutical landscape, creating a lasting legacy of innovation and progress. -Ends- About PHRMAG The Pharmaceutical Research and Manufacturers Association Gulf (PHRMAG) was founded in 2005 and represents 29 of the leading global innovative biopharmaceutical research companies in the Gulf region. Our member companies are devoted to innovating and developing medicines that enable patients to live longer, healthier, and more productive lives. PHRMAG's mission is to foster relationships with health authorities and healthcare systems to enhance provisions for patients and create a transparent environment for biopharmaceutical companies. Based on our globally-aligned Code of Ethics, we ensure responsible and transparent conduct. We shape the future of healthcare, improve patient outcomes, and enhance the value of the biopharmaceutical industry to drive progress in the Gulf Region. PHRMAG is committed to partnering with policymakers to support innovative medical research, yield progress for patients of today, and provide hope for the treatments and cures of tomorrow across the Gulf Region. For more information about PHRMAG and its initiatives, please visit Media Contact (Agency)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store